Profile

Culture

Core team

Qualification

Technology

Cooperation

Clinical testing service: Tumor personalized liquid biopsy Lung cancer detection Gastric and colorectal cancer treatment target detection Female gynecological oncology Pan-cancerous solid tumor (multi-cancer) Chemotherapy guidance Hereditary tumor detection; Tumor personalized clinical testing Lung cancer detection Gastric and colorectal cancer treatment target detection Female gynecological oncology Immunity therapy Pan-cancerous solid tumor (multi-cancer) Chemotherapy guidance Hereditary tumor detection

Health checkup products: Rui Health; Ryan

Cutting-edge research services: Single cell sequencing; T cell immune library sequencing; New antigen detection; Tumor personalized science research; High-throughput multi-omics sequencing and analysis services

News

Knowledge

Recruitment

Staff style

APP download

WeChat

Tel: +86-571-89360709 E-mail: service@repugene.com
Address: 21-23, Health Valley, No. 1500, Wenyi West Road, Yuhang District, Hangzhou, Zhejiang, China
Copyright: Hangzhou Repugene Technology Co., Ltd. Powered by www.300.cn
浙ICP备16003170号

Hangzhou Repugene Technology Co., Ltd. is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.

core team

Dr. Ding Liming

Release time：

2019/01/19 17:19

Page view

[Abstract]:

Founder of the company, senior consultant of Rip Gene;
NPC deputies, famous returnees scholars, national “Thousand Talents Program” experts, leading figures in Chinese pharmaceutical innovation, and also winners of the National Progress Award;
Fully leading Beida Pharmaceutical to complete the listing of “Kemena”, a molecular target drug for lung cancer with completely independent intellectual property rights, to break the monopoly of foreign products in this field;
Investment holding Xcovery, Kananji Medicine, Medical Kono Bio, Beida Anjin and other pharmaceutical companies.

Founder of the company, senior consultant of Rip Gene;

NPC deputies, famous returnees scholars, national “Thousand Talents Program” experts, leading figures in Chinese pharmaceutical innovation, and also winners of the National Progress Award;

Fully leading Beida Pharmaceutical to complete the listing of “Kemena”, a molecular target drug for lung cancer with completely independent intellectual property rights, to break the monopoly of foreign products in this field;

Investment holding Xcovery, Kananji Medicine, Medical Kono Bio, Beida Anjin and other pharmaceutical companies.

Ms. Lou Shengqiong